Cargando…
Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease
BACKGROUND: Debate exists regarding which endpoints most sensitively reflect day-to-day variation in chronic obstructive pulmonary disease (COPD) symptoms and are most useful in clinical practice to predict COPD exacerbations. We hypothesized that short-acting β(2)-agonist (SABA) reliever use would...
Autores principales: | Jenkins, Christine R., Postma, Dirkje S., Anzueto, Antonio R., Make, Barry J., Peterson, Stefan, Eriksson, Göran, Calverley, Peter M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546184/ https://www.ncbi.nlm.nih.gov/pubmed/26293575 http://dx.doi.org/10.1186/s12890-015-0077-0 |
Ejemplares similares
-
Early response to inhaled bronchodilators and corticosteroids as a predictor of 12-month treatment responder status and COPD exacerbations
por: Calverley, Peter M, et al.
Publicado: (2016) -
A score to predict short-term risk of COPD exacerbations (SCOPEX)
por: Make, Barry J, et al.
Publicado: (2015) -
The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials
por: Eriksson, Göran, et al.
Publicado: (2017) -
Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD
por: Calverley, Peter M, et al.
Publicado: (2016) -
mRNA-1273/salbutamol: Exacerbation of chronic obstructive pulmonary disease and lack of efficacy: case report
Publicado: (2021)